Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05445128 · ClinicalTrials.gov registry record · Phase 2
Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease
A Phase 2 study, sponsored by Ensoma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT05445128 is a Phase 2 study that was terminated before completion, run by Ensoma. The registered enrollment target is 1 participants.
The verdict
NCT05445128, a Phase 2 study, was terminated before completion, sponsored by Ensoma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This research study is designed to investigate a new potential medicine for mobilizing stem cells and apheresis collection in patients with Sickle Cell Disease. MGTA-145, the new potential medicine, will be given with plerixafor.
Interventions
- DRUG Plerixafor
- BIOLOGICAL MGTA-145
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2022-06-24 |
| Est. Completion | 2023-02-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05445128
The ClinicalTrials.gov registry entry for NCT05445128 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ensoma, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Plerixafor is the first listed.
NCT05445128 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05445128 about?
NCT05445128 is a clinical study titled "Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease". This research study is designed to investigate a new potential medicine for mobilizing stem cells and apheresis collection in patients with Sickle Cell Disease. MGTA-145, the new potential medicine, will be given with plerixafor.
What is the current status of trial NCT05445128?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2022-06-24. Estimated completion is 2023-02-02.
What interventions are being tested in trial NCT05445128?
The interventions under investigation include: Plerixafor (DRUG), MGTA-145 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05445128?
This trial is sponsored by Ensoma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.